Generic Industry Faces Downturn, Sandoz Says; MMA Changes Hurt
Executive Summary
The generic industry is facing a "downturn" in the market for products with low barriers to entry, Sandoz CEO Andreas Rummelt said Jan. 20
You may also be interested in...
Novartis Seeks To Be Generics “Powerhouse” With Eon, Hexal Acquisitions
Novartis expects the addition of Eon Labs and Hexal AG to its Sandoz division to create a generic drug "powerhouse" that will play a major role in the emerging "authorized" generics and follow-on biologics markets
Novartis Seeks To Be Generics “Powerhouse” With Eon, Hexal Acquisitions
Novartis expects the addition of Eon Labs and Hexal AG to its Sandoz division to create a generic drug "powerhouse" that will play a major role in the emerging "authorized" generics and follow-on biologics markets
Cardinal Plans Generic Cardiolite, Other Moves To Expand Generic Presence
Cardinal Health expects to market its own generic version of Bristol-Myers Squibb's cardiac imaging agent Cardiolite (technetium Tc99m sestamibi) as part of a plan to expand its role in the generic sector